Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080385 | 1.00 | HSD11B1 (0.39) | HSD11B1CTSKCA1CA2BTK | |
| SCHEMBL12883927 | 0.88 | HSD11B1 (0.41) | HSD11B1CTSKCA1CA2BTK | |
| SCHEMBL28852224 | 0.82 | CTSK (0.37) | HSD11B1CTSKCA1CA2BTK | |
| SCHEMBL5749095 | 0.79 | MEN1 (0.36) | HSD11B1CTSKCA1CA2CYP2C9 | |
| SCHEMBL29068480 | 0.77 | CTSK (0.39) | HSD11B1CTSKCA1CA2BTK | |
| SCHEMBL6187601 | 0.75 | CTSK (0.56) | HSD11B1CTSKCA1CA2BTK | |
| SCHEMBL17781920 | 0.75 | APLNR (0.37) | HSD11B1CTSKCA1CA2BTK | |
| SCHEMBL24821867 | 0.74 | BTK (0.44) | HSD11B1CTSKCA1CA2BTK | |
| SCHEMBL15191538 | 0.74 | BTK (0.44) | HSD11B1CTSKCA1CA2BTK | |
| SCHEMBL21551186 | 0.74 | CTSK (0.44) | HSD11B1CTSKCA1CA2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | HSD11B1 4515/4885CTSK 822/4885CA1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.